Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02703714 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and GM-CSF in Biliary Cancer
A Phase 2 study of Biliary Cancer, sponsored by Robin Kate Kelley.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT02703714 is a Phase 2 study of Biliary Cancer that has completed, run by Robin Kate Kelley. The registered enrollment target is 42 participants, below the 182-participant average among 9 other Biliary Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02703714, a Phase 2 study of Biliary Cancer, has completed, sponsored by Robin Kate Kelley.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at University of California, San Francisco (UCSF). This phase II study will examine the efficacy and safety of the novel combination of pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses that the combination may increase proportion of patients with overall response compared to contemporary historical controls, with acceptable safety.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Sargramostim
Study Locations (1)
California
- University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-05-06 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02703714
The ClinicalTrials.gov registry entry for NCT02703714 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 9 other Biliary Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Robin Kate Kelley, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Biliary Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02703714 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02703714 about?
NCT02703714 is a clinical study titled "Pembrolizumab and GM-CSF in Biliary Cancer". This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at University of California, San Francisco (UCSF). This phase II study will examine the efficacy and safety of the nove...
What is the current status of trial NCT02703714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-05-06. Estimated completion is 2020-12-31.
What conditions does trial NCT02703714 study?
This clinical trial studies the following conditions: Biliary Cancer.
What interventions are being tested in trial NCT02703714?
The interventions under investigation include: Pembrolizumab (DRUG), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT02703714?
This trial is sponsored by Robin Kate Kelley, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02703714 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
COMPLETED · Phase 2
-
A Study of Patients Receiving High-Dose Rate Brachytherapy
COMPLETED · Phase 2
-
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
RECRUITING
-
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
RECRUITING · NA
-
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
RECRUITING · Phase 1
-
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.